KR20140084208A - 정제된 인자 viii의 재구성 후의 안정성을 향상시키는 방법 - Google Patents

정제된 인자 viii의 재구성 후의 안정성을 향상시키는 방법 Download PDF

Info

Publication number
KR20140084208A
KR20140084208A KR1020147013298A KR20147013298A KR20140084208A KR 20140084208 A KR20140084208 A KR 20140084208A KR 1020147013298 A KR1020147013298 A KR 1020147013298A KR 20147013298 A KR20147013298 A KR 20147013298A KR 20140084208 A KR20140084208 A KR 20140084208A
Authority
KR
South Korea
Prior art keywords
factor viii
ser
leu
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147013298A
Other languages
English (en)
Korean (ko)
Inventor
카르슈텐 호른
자비네 촐너
후베르트 메츠너
슈테판 슐테
Original Assignee
시에스엘 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시에스엘 리미티드 filed Critical 시에스엘 리미티드
Publication of KR20140084208A publication Critical patent/KR20140084208A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020147013298A 2011-10-18 2012-10-18 정제된 인자 viii의 재구성 후의 안정성을 향상시키는 방법 Ceased KR20140084208A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548601P 2011-10-18 2011-10-18
US61/548,601 2011-10-18
EP11185651 2011-10-18
EP11185651.4 2011-10-18
PCT/EP2012/070701 WO2013057219A1 (en) 2011-10-18 2012-10-18 Method for improving the stability of purified factor viii after reconstitution

Publications (1)

Publication Number Publication Date
KR20140084208A true KR20140084208A (ko) 2014-07-04

Family

ID=48140377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147013298A Ceased KR20140084208A (ko) 2011-10-18 2012-10-18 정제된 인자 viii의 재구성 후의 안정성을 향상시키는 방법

Country Status (9)

Country Link
US (5) US9394353B2 (enExample)
EP (1) EP2768853A1 (enExample)
JP (2) JP2014531910A (enExample)
KR (1) KR20140084208A (enExample)
CN (1) CN103917554B (enExample)
AU (1) AU2012318292B2 (enExample)
CA (1) CA2850579A1 (enExample)
HK (1) HK1198541A1 (enExample)
WO (1) WO2013057219A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017222330A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1198541A1 (en) 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
PL3666283T3 (pl) * 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
AU2015240354A1 (en) * 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stabilization of Factor VIII without calcium as an excipient
MX2016012870A (es) * 2014-04-01 2017-05-12 Advantech Bioscience Farmacêutica Ltda Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
PL3193911T3 (pl) * 2014-07-25 2024-03-11 Csl Behring Gmbh Ulepszone preparaty czynnika VIII do stosowania do leczenia hemofilii A
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第viii因子製剤
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
MA53020A (fr) 2018-05-18 2021-05-05 Zhengzhou Gensciences Inc Protéine de fusion du fviii améliorée et utilisation associée
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CA3224729A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
JP2872255B2 (ja) 1987-01-30 1999-03-17 バイオジエン,インコーポレイティド ファクター▲viii▼の高収量生産法
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
DE69735421T2 (de) 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
AU1598200A (en) 1998-10-23 2000-05-15 Trustees Of The University Of Pennsylvania, The Systemic delivery of gene products via skin
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
EP1460131A3 (en) 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US20040192599A1 (en) 2001-06-15 2004-09-30 Schuh Andre C Gene therapy for hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
CA2770609A1 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
HK1198541A1 (en) 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017222330A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US11046749B2 (en) 2016-06-24 2021-06-29 Mogam Institute For Biomedical Research Chimera protein comprising FVIII and vWF factors, and use thereof

Also Published As

Publication number Publication date
EP2768853A1 (en) 2014-08-27
CN103917554A (zh) 2014-07-09
US20190038722A1 (en) 2019-02-07
US20210308229A1 (en) 2021-10-07
US20200268854A1 (en) 2020-08-27
US11510968B2 (en) 2022-11-29
CN103917554B (zh) 2017-03-08
US20140249086A1 (en) 2014-09-04
WO2013057219A1 (en) 2013-04-25
US9956269B2 (en) 2018-05-01
JP2017114889A (ja) 2017-06-29
HK1198541A1 (en) 2015-05-15
AU2012318292A1 (en) 2013-05-02
US20160367641A1 (en) 2016-12-22
AU2012318292B2 (en) 2015-08-20
US9394353B2 (en) 2016-07-19
US10537616B2 (en) 2020-01-21
CA2850579A1 (en) 2013-04-25
US10881717B2 (en) 2021-01-05
JP2014531910A (ja) 2014-12-04

Similar Documents

Publication Publication Date Title
US11510968B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
US9107902B2 (en) Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
KR20150144803A (ko) 복합체
US20230203195A1 (en) Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof
US20180161402A1 (en) Truncated von willebrand factor polypeptides for treating hemophilia
KR20190073576A (ko) 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
JP6072810B2 (ja) 第viii因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用
KR20140083035A (ko) 인자 viii의 생체이용률을 증가시키기 위한 황산화 글리코사미노글리칸과 하이알루로니다제의 병용 사용
KR20190085021A (ko) 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
WO2024077335A1 (en) Factor ix variant polypeptides for administration to soft tissue
US20230190881A1 (en) Subcutaneous administration of factor viii
AU2015258240A1 (en) Method of improving the stability of purified factor viii after reconstitution
EP3785726A1 (en) Factor viii protein with increased half-life
HK40079628A (en) Subcutaneous administration of factor viii
JP2020525498A (ja) 血友病の予防的処置のための第ix因子およびヒトアルブミンを含む融合タンパク質に関する21日の投与計画およびその方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170531

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180620

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180620

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I